Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Articles|May 23, 2022
Daily Medication Pearl: Kazano (Alogliptin and Metformin HCl)
Author(s)Saro Arakelians, PharmD
Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Advertisement
Medication Pearl of the Day: Kazano (Alogliptin and Metformin HCl)
Indication: Kazano is a dipeptidyl-peptidase-4 (DPP-4) inhibitor and a biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).
Insights:
- Dosing: Kazano should be taken twice daily with food.
- Dosage forms: Tablets: 12.5 mg alogliptin and 500 mg metformin HCl, 12.5 mg alogliptin and 1000 mg metformin HCl
- Adverse events: Common adverse reactions reported in ≥4% of patients treated with coadministration of alogliptin with metformin were back pain, diarrhea, headaches, hypertension, nasopharyngitis, upper-respiratory-tract infections, and urinary-tract infections.
- Mechanism of action: Kazano combines 2 antihyperglycemic agents with complementary and distinct 466 mechanisms of action to improve glycemic control in patients with T2D: alogliptin, a selective inhibitor of DPP-4, and metformin HCl, a member of the biguanide 468 class.
- Manufacturer: Takeda Pharma
Advertisement
Related to this article
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Advertisement
Advertisement